News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 639 results
September 2017
August 2017
-
Media ReleaseMultimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
-
Media ReleaseNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice- First-in-class therapy showed an 83% (52/63) overall remission rate in this patient population with limited treatment options and historically poor outcomes1,2- Novel approach to cancer treatment…
-
Media ReleaseMultimedia Assets Now Available: Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media ReleaseNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah™ (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
-
Media ReleaseNovartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones- elevateMS study allows researchers to collect sensor-based movement data and symptoms directly from participants without the need for clinic visits- Study aims to improve understanding of daily…
-
Media ReleaseNovartis launches first large-scale research study in multiple sclerosis that allows participants to contribute from smartphones
July 2017
-
Media ReleaseFDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for NovartisAMG 334 (erenumab) is an investigational therapy with a novel mechanism of action for migraine prevention for patients with high unmet needMigraine is associated with pain, disability and nearly $25…
-
Media ReleaseFDA Accepts Biologics License Application for AMG 334 (Erenumab), an Important Regulatory Milestone for Novartis
-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis- 5 year data from long-term Phase III extension study demonstrate sustained efficacy and safety of Cosentyx in patients with moderate-to-severe plaque psoriasis(1)- Data planned to be presented at a…
-
Media ReleaseNovartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
Pagination
- ‹ Previous page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- …
- 54
- › Next page